Skip to main content
SpringerLink
Log in

The Role of Topical Calcineurin Inhibitors for Skin Diseases Other Than Atopic Dermatitis

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

The topical calcineurin inhibitors (TCIs) pimecrolimus and tacrolimus are approved for atopic dermatitis but have additional potential in other inflammatory skin diseases. This article reviews their clinical use in non-atopic dermatitis diseases. In seborrheic dermatitis, asteatotic eczema, and contact dermatitis, TCIs are of great benefit and can compete with topical corticosteroids. In psoriasis, TCIs have shown clinical efficacy and safety in facial and intertriginous lesions. Further investigations into possible combinations of TCIs with other established treatments such as UVB irradiation in this disorder are necessary. Initial studies in cutaneous lupus erythematosus have been promising, whereas the response in rosacea and rosacea-like eruptions has been mixed. TCIs have been associated with good clinical responses in oral lichen planus and anogenital lichen sclerosus et atrophicus. In vitiligo, TCIs are associated with some degree of repigmentation, with better results being seen in children and in facial and neck areas. TCIs have a synergistic effect with UVB irradiation in vitiligo. There is a long list of small series and case reports documenting use of TCIs in various other skin conditions that warrant further validation. Although the established mode of action of TCIs is T-cell control, other effects also need to be considered. Specifically, TCIs reduce pruritus and erythema, which cannot be explained by T-cell interactions, and further investigations are needed in these fields.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Meingassner JG, Aschauer H, Stuetz A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol 2005; 14: 752–7

    Article  PubMed  CAS  Google Scholar 

  2. Paul C, Cork M, Rossi AB. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated up to 2 years. Pediatrics 2006; 117: 118–25

    Article  Google Scholar 

  3. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65: 827–58

    Article  PubMed  CAS  Google Scholar 

  4. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493–503

    Article  PubMed  CAS  Google Scholar 

  5. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5: 643–55

    Article  PubMed  CAS  Google Scholar 

  6. Draelos Z, Nayak A, Pariser D. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005; 53: 602–9

    Article  PubMed  Google Scholar 

  7. Sunderkötter C, Weiss JM, Bextermöller R. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and quality of life. J Dtsch Dermatol Ges 2006; 4: 301–6

    Article  PubMed  Google Scholar 

  8. Rallis E, Nasiopoulou A, Kouskoukis C. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 2004; 30: 191–5

    PubMed  CAS  Google Scholar 

  9. Rigopoulos D, Ioannides D, Kalogeromitros D. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis: a randomized open-label clinical study. Br J Dermatol 2004; 151: 1071–5

    Article  PubMed  CAS  Google Scholar 

  10. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol 2006; 54: 1083–8

    Article  PubMed  Google Scholar 

  11. Warshaw EM, Wohlhuter RJ, Liu A. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. Epub 2006 Dec 21

    Google Scholar 

  12. Firooz A, Solhpour A, Gorouhi F. Pimecrolimus cream, 1%, vs hydrocortisone acetate, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142: 1066–7

    PubMed  Google Scholar 

  13. Sugita T, Tajima M, Tsubuku H. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother 2006; 50: 2897–8

    Article  PubMed  CAS  Google Scholar 

  14. Braza TJ, DiCarlo JB, Soon SL. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003; 148: 1242–4

    Article  PubMed  CAS  Google Scholar 

  15. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145–7

    Article  PubMed  Google Scholar 

  16. Schulz P, Bunselmeyer B, Bräutigam M. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007; 21: 90–4

    Article  PubMed  CAS  Google Scholar 

  17. Castro AP. Calcineurin inhibitors in the treatment of allergic dermatitis. J Pediatr (Rio J) 2006; 82 Suppl.: 166–72

    Article  Google Scholar 

  18. Queille-Roussel C, Graeber M, Thurston M. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Derm 2000; 42: 349–50

    Article  PubMed  CAS  Google Scholar 

  19. Belsito D, Wilson DC, Warshaw E. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006; 55: 40–6

    Article  PubMed  Google Scholar 

  20. Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003; 49: 477–82

    Article  PubMed  Google Scholar 

  21. Pacor ML, Di Lorenzo G, Martinelli N. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006; 27: 527–31

    Article  PubMed  CAS  Google Scholar 

  22. Alomar A, Puig L, Gallardo CM. Topical tacrolimus 0.1% ointment (Protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Derm 2003; 49: 185–8

    Article  PubMed  CAS  Google Scholar 

  23. Belsito DV, Fowler Jr JF, Marks Jr JG. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73: 31–8

    PubMed  Google Scholar 

  24. Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17: 240–50

    Article  PubMed  Google Scholar 

  25. Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatol Ther 2004; 17: 334–40

    Article  PubMed  Google Scholar 

  26. Wollina U, Abdel-Naser MB. Pharmacotherapy of pompholyx. Exp Opin Pharmacother 2004; 5: 1517–22

    Article  CAS  Google Scholar 

  27. Bruckner AL, Weston WL. Allergic contact dermatitis in children: a practical approach to management. Skin Therapy Lett 2002; 7: 3–5

    PubMed  CAS  Google Scholar 

  28. Schurmeyer-Horst F, Luger TA, Böhm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007; 214: 99–100

    Article  PubMed  Google Scholar 

  29. Schnopp C, Remling R, Möhrenschläger M. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar erythema: a randomized, observer-blinded trial. J Am Acad Dermatol 2002; 46: 73–7

    Article  PubMed  Google Scholar 

  30. Kreuter A, Hochdorfer B, Altmeyer P. Pimecrolimus 1% cream for perianal atopic dermatitis. Br J Dermatol 2005; 152: 186–7

    Article  PubMed  CAS  Google Scholar 

  31. Lazarous MC, Kerdel FA. Topical tacrolimus Protopic. Drugs Today (Barc) 2002; 38: 7–15

    Article  Google Scholar 

  32. Ortonne JP, van de Kerkhof PC, Prinz JC. 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 2006; 86: 29–33

    PubMed  CAS  Google Scholar 

  33. Mrowietz U, Graeber M, Bräutigam M. The novel ascomycin derivate SDZ ASM 981 is effective in psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992–6

    Article  PubMed  CAS  Google Scholar 

  34. Griebetz C, Ling M, Lebwohl M. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731–8

    Article  Google Scholar 

  35. Kreuter A, Sommer A, Hyun J. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142: 1138–43

    Article  PubMed  CAS  Google Scholar 

  36. Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17: 364–75

    Article  PubMed  Google Scholar 

  37. Freeman AK, Linkowski GJ, Brady C. Tacrolimus ointment for the treatment of psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564–8

    Article  PubMed  Google Scholar 

  38. Rallis E, Nasiopoulou A, Kouskoukis C. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 2005; 31: 141–5

    PubMed  CAS  Google Scholar 

  39. Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006; 5: 334–6

    Google Scholar 

  40. Yamamoto T, Nishioka K. Topical tacrolimus: an effective treatment for facial psoriasis. Eur J Dermatol 2003; 13: 471–3

    PubMed  CAS  Google Scholar 

  41. Carroll CL, Clarke J, Camacho F. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005; 141: 43–6

    Article  PubMed  CAS  Google Scholar 

  42. Lebwohl M, Freeman AK, Chapman MS. Tacrolimus is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723–30

    Article  PubMed  Google Scholar 

  43. Wilsmann-Theis D, Hagemann T, Dederer H. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol 2004; 150: 1194–7

    Article  PubMed  CAS  Google Scholar 

  44. Nagao K, Ishiko A, Yokoyama T. A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003; 139: 1219

    PubMed  Google Scholar 

  45. Brill TJ, Elshorst-Schmidt T, Valesky EM. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology 2005; 211: 351–5

    Article  PubMed  Google Scholar 

  46. Rodríguez García F, Fagundo Gonzí1lez E, Cabrera-Paz R. Generalized pustular psoriasis successfully treated with topical tacrolimus. Br J Dermatol 2005; 152: 587–8

    Article  Google Scholar 

  47. Rivard J, Janiga J, Lim HW. Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drugs Dermatol 2006; 5: 505–10

    PubMed  Google Scholar 

  48. Afifi T, de Gannes G, Huang C. Topical therapies for psoriasis: evidence-based review. Can Fam Physician 2005 Apr; 51: 519–25

    PubMed  Google Scholar 

  49. Tan JKL, Morneau K, Fung K. Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris. J Am Acad Dermatol 2005; 52: 738–9

    Article  PubMed  Google Scholar 

  50. Barr J, Friedman A. Use of imiquimod and pimecrolimus cream in the treatment of acne keloidalis nuchae [abstract]. J Am Acad Dermatol 2005; 52: 64

    Article  Google Scholar 

  51. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005; 4: 147–50

    Article  PubMed  Google Scholar 

  52. Chu C-Y. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396–9

    Article  PubMed  Google Scholar 

  53. Meykadeh N, Meiss F, Marsch WC. Steroid-aggravated rosacea: successful therapy with pimecrolimus [in German]. Hautarzt 2007 Apr; 58 (4): 338–42

    Article  PubMed  CAS  Google Scholar 

  54. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001; 44: 995–8

    Article  PubMed  CAS  Google Scholar 

  55. Pabby A, An KP, Laws RA. Combination therapy of tetracycline and tacrolimus resulting in rapid resolution of steroid-induced periocular rosacea. Cutis 2003; 72: 141–2

    PubMed  Google Scholar 

  56. Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream [letter]. Arch Dermatol 2005; 141: 1168

    Article  PubMed  Google Scholar 

  57. Bernard LA, Cunningham BB, Al-Suwaidan S. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol 2003; 139: 229–31

    PubMed  Google Scholar 

  58. El Sayed F, Ammoury A, Dhaybi R. Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol 2006; 54: 548–50

    Article  PubMed  Google Scholar 

  59. Tlaculio-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1564–8

    Article  CAS  Google Scholar 

  60. Kreuter A, Gambichler T, Breuckmann F. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51: 407–10

    Article  PubMed  Google Scholar 

  61. Lampropoulos CE, Sangle S, Harrison P. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology 2004; 43: 1383–5

    Article  PubMed  CAS  Google Scholar 

  62. Sugano M, Shitani Y, Kobayashi K. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006; 33: 887–9

    Article  PubMed  Google Scholar 

  63. Yoshimasu T, Ohtani T, Sakamoto T. Topical FK 506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatofor myositis. Eur J Dermatol 2002; 12: 50–2

    PubMed  Google Scholar 

  64. Böhm M, Gaubitz M, Luger TA. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus: a report of three cases. Dermatology 2003; 207: 381–5

    Article  PubMed  CAS  Google Scholar 

  65. Von Pelchrzim R, Schmook T, Friedrich M. Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. Int J Dermatol 2006; 45: 84–5

    Article  Google Scholar 

  66. Kanekura T, Yoshii N, Terasaki K. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148: 353–6

    Article  PubMed  CAS  Google Scholar 

  67. Rubegni P, Sbano P, Risulo M. A case of reticular erythematous mucinosis treated with topical tacrolimus. Br J Dermatol 2004; 150: 173–4

    Article  PubMed  CAS  Google Scholar 

  68. Tzung T-Y, Wu J-C. Topical calcineurin inhibitors in treating Jessner’s lymphocytic infiltration of the skin: report of a case. Br J Dermatol 2005; 152: 383–4

    Article  PubMed  Google Scholar 

  69. Peyrot I, Sparsa A, Loustad-Ratti V. Topical tacrolimus and resistant lesions of dermatomyositis. Rev Med Interne 2006; 27: 730–5

    Article  PubMed  CAS  Google Scholar 

  70. Ueda M, Makinodan R, Matsumara M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol 2003; 148: 595–6

    Article  PubMed  CAS  Google Scholar 

  71. Lampropoulos CE, D’Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005; 64: 1376–7

    Article  PubMed  CAS  Google Scholar 

  72. Garcia-Doval I, Cruses M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology 2004; 209: 247–8

    Article  PubMed  CAS  Google Scholar 

  73. Manusco G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol 2003; 13: 590–2

    Google Scholar 

  74. Santos-Juanes J, Sanchez del Rio J, Galache C. Topical tacrolimus: an effective therapy for Zoon balanitis. Arch Dermatol 2004; 140: 1538–9

    Article  PubMed  Google Scholar 

  75. Hernandez-Machin B, Borrego Hernando L, Báez Marrero O. Plasma cell balanitis of Zoon treated successfully with topical tacrolimus. Clin Exp Dermatol 2005; 30: 588–9

    Article  PubMed  CAS  Google Scholar 

  76. De Almeida HL, de Oliveira Filho UL. Topical pimecrolimus is an effective treatment for balanitis circinata erosiva. Int J Dermatol 2005; 44: 888–9

    Article  PubMed  Google Scholar 

  77. Moreno-Arias GA, Camps-Fresneda A, Llaberia C. Plasma cell balanitis treated with tacrolimus 0.1%. Br J Dermatol 2005; 153: 1204–6

    Article  PubMed  CAS  Google Scholar 

  78. Roé E, Dalmau J, Peramiquel L. Plasma cell balanitis of Zoon treated with topical tacrolimus 0.1%; report of three cases. J Eur Acad Dermatol Venereol 2007; 21: 284–5

    PubMed  Google Scholar 

  79. Almeida Jr HL, Oliveira Filho UL. Topical pimecrolimus is an effective treatment for balanitis circinata erosive. Int J Dermatol 2005; 44: 888–9

    Article  PubMed  Google Scholar 

  80. Davatchi F. New and innovative therapies for Behcet’s disease. APLAR J Rheumatol 2004; 7: 141–5

    Article  Google Scholar 

  81. Lin P, Liang G. Behcet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 2006; 12: 282–6

    Article  PubMed  Google Scholar 

  82. Lim SJ, Love EW. Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J Drugs Dermatol 2004; 3: 563–4

    PubMed  Google Scholar 

  83. Lonsdale-Eccles AA, Velangi S. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br J Dermatol 2005; 153: 390–4

    Article  PubMed  CAS  Google Scholar 

  84. Byrd JA, Davis MDP, Rogers III RS. Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus. Arch Dermatol 2004; 140: 715–20

    Article  PubMed  Google Scholar 

  85. Jensen JT, Bird M, Leclair CM. Patient satisfaction after the treatment of vulvovaginal erosive lichen planus with topical clobetasol and tacrolimus: a survey study. Am J Obstet Gynecol 2004; 190: 1759–63

    Article  PubMed  Google Scholar 

  86. Kaliakatsou F, Hodgson TA, Lewsey JD. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002; 46: 35–41

    Article  PubMed  CAS  Google Scholar 

  87. Rozycki TW, Rogers III RS, Pittelkow MR. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002; 46: 27–34

    Article  PubMed  Google Scholar 

  88. Morrison L, Kratochvil III FJ, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002; 47: 617–20

    Article  PubMed  Google Scholar 

  89. Thomson MA, Hamburger J, Stewart DG. Treatment of erosive oral lichen planus with topical tacrolimus. J Dermatolog Treat 2004; 15: 308–15

    Article  PubMed  CAS  Google Scholar 

  90. Byrd JA, Davis MD, Bruce AJ. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 2004; 140: 1508–12

    Article  PubMed  CAS  Google Scholar 

  91. Scheer M, Kawari-Mahmoodi N, Neugebauer J. Pimecrolimus (Elidel®) for therapy of lichen ruber mucosae. deMund Kiefer Gesichtschir 2006; 10: 403–7

    Article  CAS  Google Scholar 

  92. Esquivel-Pedraza L, Fernández-Cuevas L, Ortíz-Pedroza G. Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004; 150: 771–3

    Article  PubMed  CAS  Google Scholar 

  93. Laeijendecker R, Tank B, Dekker SK. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006; 86: 227–9

    Article  PubMed  CAS  Google Scholar 

  94. Mattsson U, Jontell M, Holmstrup P. Oral lichen planus and malignant transformation: is a recall of patients justified? Crit Rev Oral Biol Med 2002; 13: 390–6

    Article  PubMed  Google Scholar 

  95. Ring J, Barker J, Behrendt H. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005; 19: 663–71

    Article  PubMed  CAS  Google Scholar 

  96. Berger TG, Duvic M, Van Voorhees AS. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818–23

    Google Scholar 

  97. Simpkin S, Oakley A. Clinical review of 202 patients with vulval lichen sclerosus: a possible association with psoriasis. Australas J Dermatol 2007 Feb; 48 (1): 28–31

    Article  PubMed  Google Scholar 

  98. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004; 49: 778–80

    PubMed  Google Scholar 

  99. Nissi R, Eriksen H, Risteli J. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest 2006; 63: 151–4

    Article  PubMed  CAS  Google Scholar 

  100. Virgili A, Lauriola MM, Mantovani L. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol 2007; 87: 69–72

    Article  PubMed  CAS  Google Scholar 

  101. Hengge U, Krause W, Hofman H. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol 2006; 155: 1021–8

    Article  PubMed  CAS  Google Scholar 

  102. Boms S, Gambichler T, Freitag M. Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatol 2004; 4: 14

    Article  PubMed  CAS  Google Scholar 

  103. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004; 17: 35–7

    Article  PubMed  Google Scholar 

  104. Matsumoto Y, Yamamoto T, Isobe T. Successful treatment of vulvar lichen sclerosus in a child with low-concentration topical tacrolimus ointment. J Dermatol 2007; 34: 114–6

    Article  PubMed  CAS  Google Scholar 

  105. Aricano O, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol 2004; 31: 1014–7

    Google Scholar 

  106. Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293: 730–5

    Article  PubMed  CAS  Google Scholar 

  107. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88–91

    PubMed  Google Scholar 

  108. Dawid M, Veensalu M, Grassberger M. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006; 4: 942–6

    Article  PubMed  Google Scholar 

  109. Boone B, Onganae K, Van Geel N. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007; 17: 55–61

    PubMed  CAS  Google Scholar 

  110. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789–91

    Article  PubMed  Google Scholar 

  111. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158–62

    PubMed  Google Scholar 

  112. Lepe V, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581–5

    Article  PubMed  CAS  Google Scholar 

  113. Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhoodvitiligo in Asians. Clin Exp Dermatol 2004; 29: 589–92

    Article  PubMed  CAS  Google Scholar 

  114. Almeida P, Borrego L, Rodriguez-Lopez J. Vitiligo: treatment of 12 cases with topical tacrolimus. Actas Dermatosifiliogr 2005; 96: 159–63

    Article  Google Scholar 

  115. Passeron T, Ostovari N, Zakaria W. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065–9

    Article  PubMed  CAS  Google Scholar 

  116. Ostovari N, Passeron T, Lacour JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006; 142: 252–3

    Article  PubMed  Google Scholar 

  117. Oji V, Beljan G, Beiner K. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153: 1067–8

    Article  PubMed  CAS  Google Scholar 

  118. Thaci D, Pätzold S, Schwanner S. Comel-Netherton syndrome: a case treated with topical pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2004; 18 Suppl. 2: 160–1

    Google Scholar 

  119. Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int J Dermatol 2005; 45: 693–7

    Article  Google Scholar 

  120. Allen A, Siegfried E, Silverman R. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747–50

    PubMed  CAS  Google Scholar 

  121. Bens G, Boralevi F, Buenet C. Topical treatment of Netherton’s syndrome with tacrolimus ointment without significant systemic absorption. Br J Dermatol 2003; 149: 224–5

    Article  PubMed  CAS  Google Scholar 

  122. Saif GB, Al-Kenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int J Dermatol 2006; 46: 290–4

    Article  Google Scholar 

  123. Bienemann K, Gudowius S, Niehues T. Topical tacrolimus is effective against eczema in Wiskott-Aldrich syndrome (WAS). Acta Paediatr 2007; 96: 312–4

    Article  PubMed  Google Scholar 

  124. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002; 2: 149–58

    Article  Google Scholar 

  125. Lyon CC, Smith AJ, Beck MH. Parastomal pyoderma gangrenosum: clinical features and management. J Am Acad Dermatol 2000; 42: 992–1002

    Article  PubMed  CAS  Google Scholar 

  126. Khurrum Baig M, Marquez H, Nogueras JJ. Topical tacrolimus (FK506) in the treatment of parastomal pyoderma gangrenosum associated with Crohn’s disease: report of two cases. Colorectal Dis 2004; 6: 250–3

    Article  Google Scholar 

  127. Chiba T, Isomura I, Suzuki A. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005; 32: 199–203

    PubMed  Google Scholar 

  128. Lally A, Hollowood K, Bunker CB. Penile pyoderma gangrenosum treated with topical tacrolimus. Arch Dermatol 2005; 141: 1175–6

    Article  PubMed  Google Scholar 

  129. Deckers-Kocken JM, Pasmans SGMA. Successful tacrolimus (FK506) therapy in a child with pyoderma gangrenosum [letter]. Arch Dis Child 2005; 90: 531

    Article  PubMed  CAS  Google Scholar 

  130. Rabeni EJ, Cunningham NM. Effective treatment of Hailey-Hailey disease with topical tacrolimus. J Am Acad Dermatol 2002; 47: 797–8

    Article  PubMed  Google Scholar 

  131. Sand C, Thomsen HK. Topical tacrolimus ointment is an effective therapy for Hailey-Hailey disease. Arch Dermatol 2003; 139: 1401–2

    Article  PubMed  Google Scholar 

  132. Umar S, Bhattacharjee P, Brodell RT. Treatment of Hailey-Hailey disease with tacrolimus ointment and clobetasol propionate foam. J Drugs Dermatol 2004; 3: 200–3

    PubMed  Google Scholar 

  133. Reuter J, Termeer C, Bruckner-Tuderman L. Tacrolimus: a new therapeutic option for Hailey-Hailey-disease? J Dtsch Dermatol Ges 2005; 3: 278–9

    PubMed  Google Scholar 

  134. Gach JE, Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol 2004; 29: 271–2

    Article  PubMed  CAS  Google Scholar 

  135. Termeer CC, Techau K, Augustin M. Topical tacrolimus (Protopic) for the treatment of a localized pemphigus foliaceus. J Eur Acad Dermatol Venereol 2004; 18: 636–7

    Article  PubMed  CAS  Google Scholar 

  136. Cohen SN, Lim RPR, Paul CJ. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus [letter]. Int J Dermatol 2006; 45: 1379

    Article  PubMed  Google Scholar 

  137. Hall VC, Liesegang TJ, Kostick DA. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139: 1083–4

    Article  PubMed  Google Scholar 

  138. Günther C, Wozel G, Meuerer M. Topical tacrolimus treatment for cicatricial pemphigoid. J Am Acad Dermatol 2004; 50: 325–6

    Article  PubMed  Google Scholar 

  139. Assmann T, Becker J, Ruzicka T. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol 2004; 29: 674–6

    Article  PubMed  CAS  Google Scholar 

  140. Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006; 26: 66–70

    Article  PubMed  Google Scholar 

  141. Wenzel J, Philipp-Dormston W, Bieber T. Topical treatment of bullous pemphigoid with tacrolimus: case report with brief literature review. J Dtsch Dermatol Ges 2005; 3: 207–10

    Article  PubMed  Google Scholar 

  142. Schmook T, Kraft J, Benninghoff B. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005; 36: 87–8

    Article  PubMed  CAS  Google Scholar 

  143. Elad S, Or R, Resnick I. Topical tacrolimus: a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 2003; 16: 665–70

    PubMed  CAS  Google Scholar 

  144. Heinemann C, Kaatz M, Schreiber G. Topical tacrolimus in severe chronic graft-versus-host disease. Acta Derm Venereol 2005; 85: 370–1

    Article  PubMed  Google Scholar 

  145. Ziemer M, Gruhn M, Thiele JJ. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol 2004; 50: 946–8

    Article  PubMed  Google Scholar 

  146. Neuman DL, Farrar JE, Moresi JM. Toxic absorption of tacrolimus in a patient with severe acute graft-versus-host disease. Bone Marrow Transplant 2005; 36: 919–20

    Article  PubMed  CAS  Google Scholar 

  147. Eckardt A, Starke O, Stadler M. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004; 40: 811–4

    Article  PubMed  Google Scholar 

  148. Sanchez AR, Sheridan PJ, Rogers RS. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 2004; 75: 613–9

    Article  PubMed  Google Scholar 

  149. Casson DH, Eltumi M, Tomlin S. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn’s disease. Gut 2000; 47: 436–40

    Article  PubMed  CAS  Google Scholar 

  150. Corrocher G, Di Lorenzo G, Mansueto P. Comparison of topical tacrolimus 0.1% in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: a 4-week, randomized, double-blind clinical trial. Clin Ther 2006; 28: 1296–302

    Article  PubMed  CAS  Google Scholar 

  151. Almeida Jr HL. Successful treatment of chronic actinic dermatitis with topical pimecrolimus. Int J Dermatol 2005; vn44: 343–4

    Article  Google Scholar 

  152. Uetsu N, Okamoto H, Fuji K. Treatment of chronic actinic dermatitis with tacrolimus ointment. J Am Acad Dermatol 2002; 47: 881–4

    Article  PubMed  Google Scholar 

  153. Ogawa Y, Adachi A, Tomita Y. The successful use of topical tacrolimus treatment for a chronic actinic dermatitis patient with a complication of idiopathic leukopenia. J Dermatol 2003; 30: 805–9

    PubMed  Google Scholar 

  154. Evans AV, Palmer RA, Hawk JL. Erythrodermic chronic actinic dermatitis responding only to topical tacrolimus. Photodermatol Photoimmunol Photomed 2004; 20: 59–61

    Article  PubMed  CAS  Google Scholar 

  155. Djalilia HR, Memar O. Topical pimecrolimus 1% for the treatment of pruritic external auditory canals. Laryngoscope 2006; 116: 1809–12

    Article  CAS  Google Scholar 

  156. Sarifakioglu E, Gumus II. Efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus: a prospective case series: a non-controlled open-label study. J Dermatolog Treat 2006; 17: 276–8

    Article  PubMed  CAS  Google Scholar 

  157. Connolly M, Kennedy C. Exfoliative cheilitis successfully treated with topical tacrolimus. Br J Dermatol 2004; 151: 241–2

    Article  PubMed  CAS  Google Scholar 

  158. Rubegni P, Poggiali S, Risulo M. A case of Darier’s disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol 2005; 20: 84–7

    Article  Google Scholar 

  159. Suga Y, Tsuboi R, Hashimoto Y. A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus. J Am Acad Dermatol 2000; 42: 520–2

    Article  PubMed  CAS  Google Scholar 

  160. Simon D, Boudny C, Nievergelt H. Successful treatment of pityriasis lichenoides with topical tacrolimus. Br J Dermatol 2004; 150: 1033–5

    Article  PubMed  CAS  Google Scholar 

  161. Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002; 147: 154–6

    Article  PubMed  CAS  Google Scholar 

  162. Harth W, Linse R. Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. Br J Dermatol 2004; 150: 792–4

    Article  PubMed  CAS  Google Scholar 

  163. Castanedo-Cazares JP, Lepe V, Moncada B. Lichen amyloidosis improved by 0.1% topical tacrolimus. Dermatology 2002; 205: 420–1

    Article  PubMed  Google Scholar 

  164. Marcoval J, Moreno A, Bordas X. Granuloma faciale: treatment with topical tacrolimus. J Am Acad Dermatol 2006; 55 Suppl.: 110–1

    Article  Google Scholar 

  165. Hara D, Kuroda K, Mieno H. Treatment of eosinophilic pustular folliculitis with tacrolimus ointment. J Am Acad Dermatol 2004; 51 Suppl.: 143–5

    Article  Google Scholar 

  166. Sáez M, Rodríguez-Martín M, Sidro M. Successful treatment of erosive pustular dermatosis of the scalp with topical tacrolimus. Clin Exp Dermatol 2005; 30: 578–602

    Article  Google Scholar 

  167. Rho NK, Kim BJ. Eosinophilic pustular folliculitis: successful treatment with topical pimecrolimus. Clin Exp Dermatol 2006; 32: 108–9

    Google Scholar 

  168. Laffitte E, Kaya G, Piguet V. Erosive pustular dermatosis of the scalp: treatment with topical tacrolimus. Arch Dermatol 2003; 139: 712–4

    Article  PubMed  Google Scholar 

  169. Brouard MC, Prins C, Chavaz P. Erosive pustular dermatosis of the leg: report of three cases. Br J Dermatol 2002; 147: 765–9

    Article  PubMed  CAS  Google Scholar 

  170. Mutasim DF. Successful treatment of inflammatory linear verrucous epidermal nevus with tacrolimus and fluocinonide. J Cutan Med Surg 2006; 10: 45–7

    PubMed  Google Scholar 

  171. El-Dars LD, Statham BN, Blackford S. Lymphocytoma cutis treated with topical tacrolimus. Clin Exp Dermatol 2005; 30: 305–7

    Article  PubMed  CAS  Google Scholar 

  172. Rallis E, Economidi A, Verros C. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J Drugs Dermatol 2006; 5: 906–7

    PubMed  Google Scholar 

  173. Mackelfresh J, Soon S, Arbiser JL. Combination of doxycycline and topical tacrolimus for venous ulcers. Arch Dermatol 2005; 141: 1476–7

    Article  PubMed  Google Scholar 

  174. Campbell FA, Gupta G. Lichenoid tattoo reaction responding to topical tacrolimus ointment. Clin Exp Dermatol 2005; 31: 293–4

    Article  Google Scholar 

  175. Mercader P, de la Cuadra-Oyanguren J, Rodriguez-Serna M. Treatment of protein contact dermatitis with topical tacrolimus. Acta Derm Venereol 2005; 85 (6): 555–6

    PubMed  CAS  Google Scholar 

  176. Moody BR, Sengelmann RD. Topical tacrolimus in the treatment of bovine collagen hypersensitivity. Dermatol Surg 2001; 27: 789–91

    Article  PubMed  CAS  Google Scholar 

  177. Shipley DR, Kennedy CTC. Juvenile plantar dermatosis responding to topical tacrolimus ointment. Clin Exp Dermatol 2006; 31: 453–4

    Article  PubMed  CAS  Google Scholar 

  178. Edmonds EVJ, Riaz SN, Francis N. Nodular prurigo responding to topical tacrolimus. Br J Dermatol 2004; 150: 1216–7

    Article  PubMed  CAS  Google Scholar 

  179. Rodriguez-Martin M, Saez-Rodriguez M, Carnerero-Rodriguez A. Treatment of perioral dermatitis with topical pimecrolimus. J Am Acad Dermatol 2007; 56: 529–30

    Article  PubMed  Google Scholar 

  180. Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br J Dermatol 2005; 152: 803–9

    Article  Google Scholar 

  181. Lee HW, Jeong YI, Choi JC. Two cases of telangiectasia macularis eruptiva perstans demonstrated by immunohistochemistry for c-kit (CD 117). J Dermatol 2005; 32: 817–20

    PubMed  Google Scholar 

  182. Almeida Jr HL. Treatment of steroid-resistant nodular scabies with topical pimecrolimus. J Am Acad Dermatol 2005; 53: 357–8

    Article  PubMed  Google Scholar 

  183. Suli DJ, Harford R, O’Neill JT. Discrete popular form of lichen myxedematosus: a case report and review of the literature. Cutis 2005; 75: 105–12

    Google Scholar 

  184. Böhm M, Bonsmann G, Luger TA. Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. Br J Dermatol 2004; 150: 519–20

    Article  Google Scholar 

  185. Rigopoulos D, Prantsidis A, Christofidou E. Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br J Dermatol 2005; 152: 1364–5

    Article  PubMed  CAS  Google Scholar 

  186. Eetam I, Ertekin B, Unal I. Granuloma faciale: is it a new indication for pimecrolimus? J Dermatolog Treat 2006; 17: 238–40

    Article  PubMed  Google Scholar 

  187. Hafner C, Hohenleutner U, Babilas P. Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology 2006; 213: 163–5

    Article  PubMed  Google Scholar 

  188. Kus S, Ince U. Lichen striatus in an adult patient treated with pimecrolimus. J Eur Acad Dermatol Venereol 2006; 20: 341–62

    Article  Google Scholar 

  189. Pock L, Svrcková M, Machácková R. Pimecrolimus is effective in Fox-Fordyce disease. Int J Dermatol 2006; 45: 1134–5

    Article  PubMed  Google Scholar 

  190. FDA.FDA Public Health Advisory: January 19, 2006 [online]. Available from URL: http://www.fda.gov./bbs/topics/news/2006/NEW1299.html [Accessed 2006 Sep 30

  191. Saitta P, Brancaccio R. Allergic contact dermatitis to pimecrolimus. Contact Derm 2007; 56: 43–4

    Article  PubMed  Google Scholar 

  192. Shaw DW, Maibach HI, Eichenfield LF. Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy. J Am Acad Dermatol 2007; 56: 342–5

    Article  PubMed  Google Scholar 

  193. Andersen KE, Broesby-Olsen S. Allergic contact dermatitis from oleyl alcohol in Elidel® cream. Contact Derm 2006; 55: 354–6

    Article  PubMed  CAS  Google Scholar 

  194. Lübbe J, Sanchez-Plitta S. Propolis, beeswax, and the sensitization potential of topical calcineurin inhibitors. Clin Exp Dermatol 2005; 31: 147–8

    Article  Google Scholar 

  195. Knight AK, Boxer M, Chandler MJ. Alcohol-induced rash caused by topical tacrolimus. Ann Allergy Asthma Immunol 2005; 95: 291–2

    Article  PubMed  Google Scholar 

  196. Milingou M, Antille C, Sorg O. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 2004; 140: 1522–4

    Article  Google Scholar 

  197. Sackett DL, Rosenberg WM. The need for evidence-based medicine. J R Soc Med 1995; 88: 620–4

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The author has received lecturing honoraria from Novartis and Fujisawa.

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergology, Academic Teaching Hospital of the Technical University of Dresden, Friedrichstrasse 41, Dresden, 01067, Germany

    Uwe Wollina

Authors
  1. Uwe Wollina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Wollina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wollina, U. The Role of Topical Calcineurin Inhibitors for Skin Diseases Other Than Atopic Dermatitis. AM J Clin Dermatol 8, 157–173 (2007). https://doi.org/10.2165/00128071-200708030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200708030-00003

Keywords

Search

Navigation